This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy to address motor fluctuations in advanced Parkinson’s disease.
Medscape Medical News